Belarus / Germany / Switzerland / Romania / Hungary / Netherlands / Croatia / Italy / Estonia / Belgique / Slovenia / Bulgaria / Serbia / Macedonia / Sweden / Latvia / New Zealand / Poland / Montenegro / Norway / Belgium / Turkey / France / Bosnia and Herzegovina / Russia / Austria / United States / Iceland / Australia / Portugal / Moldova / Slovakia / United Kingdom / China / Lithuania / Israel / Finland / Ukraine / Spain / Greece / Ireland / Denmark / Czech Republic / /
IndustryTerm
final products / pharmaceuticals / regulatory solutions / /
Organization
Royal Irish Academy / Court of Justice / Royal Society of London / Berlin Brandenburg Academy of Sciences and Humanities / European Academy of Arts / Sciences and Humanities / Polish Academy of Arts and Sciences / Court of European Communities / Hungarian Academy of Sciences / German Patent Office / Royal Society of Edinburgh / Polish Academy of Sciences / ALLEA Standing Committee on Intellectual Property Rights / Royal Academy of Sciences / Letters and Fine Arts of Belgium / Norwegian Academy of Arts and Sciences / Enlarged Board of Appeal / EPC / Royal Netherlands Academy of Arts and Sciences / Associated Academy / European Patent Office / Turkish Academy of Sciences / Greenpeace / European Union / Royal Society / British Academy / Council of Europe / German Federal Supreme Court / /
Person
Ed Noort / Oliver Brüstle / Sylvester Vizi / Joseph Straus / Tomasz Twardowski / Alain Strowel / William Cornish / Roger Elliott / Daniela Jezova / Feer Verkade / Ünal Tekinalp / Günter Stock / Are Stenvik / Carine Doutrelepont / Stanislaw Soltysinski / Ed Noort Postal / /
ALLEA Statement on Patentability of Inventions Involving Human Embryonic Pluripotent Stem Cells in Europe of May 2011 and the Judgment of the Court of European Communities (Grand Chamber) of 18 October 2011 in Case C-34/